Sun Pharmaceutical Industries
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sun Pharmaceutical Industries sits in the top decile of US sponsors by registered trial count (#386 of 15,742 sponsors by registered trial count).
Sun Pharmaceutical Industries: 48 sponsored US clinical trials, 1 recruiting.
Sun Pharmaceutical Industries sponsors 48 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 43 completed. 11 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 4 trials.
Top-decile sponsor footprint
Sun Pharmaceutical Industries ranks in the top decile of sponsors by registered trial count (#386 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
43 of 44 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
48 total, page 1 of 1
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
NCT07144852
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
NCT07144345
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
NCT03898479
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
NCT07546214
A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris
NCT07469228
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
NCT06733402
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
NCT06673641
A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
NCT06305637
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
NCT06673654
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
NCT06063473
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
NCT05282771
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
NCT04883593
A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
NCT04883736
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
NCT04797793
A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris
NCT04724473
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
NCT04321070
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
NCT04134273
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
NCT03880357
An Open-Label Study to Assess Safety
NCT03645499
Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream
NCT04358770
A Study Comparing Oxymetazoline 1% Cream to RHOFADE
NCT05148689
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
NCT03689010
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
NCT03427554
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
NCT03433378
A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
NCT03257943
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
NCT02932878
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
NCT02932891
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
NCT02933502
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
NCT02933528
Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study
NCT02933879
Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
NCT02933866
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
NCT02601469
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
NCT02595073
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
NCT02618759
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
NCT02595008
Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis
NCT02340169
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
NCT01513863
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
NCT01206660
Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study
NCT01043393
Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
NCT01018134
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
NCT00927472
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
NCT00963508
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
NCT00752973
Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis
NCT00835510
Bioequivalence Study of Two Imiquimod Cream 5%
NCT00828568
Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice
NCT00291057
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice
NCT00244439
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 12 |
| Phase 3 | 10 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Sun Pharmaceutical Industries pipeline
1 recruiting of 48 indexed (2% open); 43 completed (90%).
Phase mix: 11 late (III/IV) vs 37 early (I/II) (early-phase heavy).
Top condition: Acne Vulgaris (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sun Pharmaceutical Industries: open-pipeline peers nationwide
Peers matched on 48 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Sun Pharmaceutical Industries sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 48 trials (± recruiting share)
- Albert Einstein Healthcare Network · 48 trials · 6% recruiting
- Exelixis · 48 trials · 17% recruiting
- Walter Reed National Military Medical Center · 48 trials · 27% recruiting
- Alnylam Pharmaceuticals · 49 trials · 29% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Cynosure · 2% recruiting · 49 trials
- Genzyme, a Sanofi Company · 2% recruiting · 196 trials
- USDA, Western Human Nutrition Research Center · 2% recruiting · 47 trials
- Centers for Disease Control and Prevention · 2% recruiting · 139 trials
Related
What to do with this Sun Pharmaceutical Industries page
48 registered trials is a research-attention snapshot, not an endorsement of Sun Pharmaceutical Industries or any single study.
- 1 of Sun Pharmaceutical Industries's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Sun Pharmaceutical Industries studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sun Pharmaceutical Industries pipeline card: 48 registered trials from official public datasets.Report a data error.